Paradigm is a non-profit corporation established to bring cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.  Through Next-Gen Sequencing, and other biomarker analysis, Paradigm is able to provide information about the genomic and proteomic landscape of a patient’s cancer, as well as potential therapies based on the specific characterization of the patient’s tumor; thus, personalizing each patient’s course of treatment.